| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/30/2009 | US20090191224 Nucleolin-Mediated Cancer Diagnostics and Therapy |
| 07/30/2009 | US20090191223 Peptides that selectively home to heart vasculature and related conjugates and methods |
| 07/30/2009 | US20090191222 Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression |
| 07/30/2009 | US20090191221 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| 07/30/2009 | US20090191220 Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| 07/30/2009 | US20090191219 Methods for diagnosing and treating obesity by modulating the activity of auto-antibodies against the melanocortin-4 receptor |
| 07/30/2009 | US20090191218 DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| 07/30/2009 | US20090191217 Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses |
| 07/30/2009 | US20090191216 Antibody or a fragment thereof, having neutralizing activity against HIV |
| 07/30/2009 | US20090191215 Treatment with anti-VEGF Antibodies |
| 07/30/2009 | US20090191214 Anti-human il-21 monoclonal antibodies |
| 07/30/2009 | US20090191213 Compositions and methods for regulating NK cell activity |
| 07/30/2009 | US20090191212 Heavy chain fragments, light chain fragments, and CDRs of fully human antibodies, that bind to angiopoietin-2; inhibits undesired angiogenesis |
| 07/30/2009 | US20090191211 METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES |
| 07/30/2009 | US20090191210 Method for inhibiting tumor invasion or spreading in a subject |
| 07/30/2009 | US20090191209 Methods and compositions for targeting polyubiquitin |
| 07/30/2009 | US20090191208 Antibodies against flagellin and uses thereof |
| 07/30/2009 | US20090191207 Compositions and methods for the prophylaxis or treatment of viral diseases |
| 07/30/2009 | US20090191206 Human Semen Enhancer of Viral Infection Peptides (SEVI) and Their Use |
| 07/30/2009 | US20090191205 Compositions and Methods for Treating and Diagnosing Cancer |
| 07/30/2009 | US20090191204 Anti-psgl-1 antibodies |
| 07/30/2009 | US20090191203 Bcma Polypeptides And Uses Thereof |
| 07/30/2009 | US20090191202 Methods for manipulating phagocytosis mediated by CD47 |
| 07/30/2009 | US20090191201 Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| 07/30/2009 | US20090191200 Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity |
| 07/30/2009 | US20090191199 Glycoengineered, recombinant antibody |
| 07/30/2009 | US20090191198 Methods for blocking the interaction between nkp80 and its ligands |
| 07/30/2009 | US20090191197 Cancerous disease modifying antibodies |
| 07/30/2009 | US20090191196 Use |
| 07/30/2009 | US20090191195 Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof |
| 07/30/2009 | US20090191193 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof |
| 07/30/2009 | US20090191192 Humanized anti-ccr2 antibodies and methods of use therefor |
| 07/30/2009 | US20090191191 Methods for the Modulation of IL-13 |
| 07/30/2009 | US20090191190 Anti-ABeta Globulomer Antibodies, Antigen-Binding Moieties Thereof, Corresponding Hybridomas, Nucleic Acids, Vectors, Host Cells, Methods of Producing Said Antibodies, Compositions Comprising Said Antibodies, Uses Of Said Antibodies And Methods Of Using Said Antibodies |
| 07/30/2009 | US20090191189 Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| 07/30/2009 | US20090191188 Immunostimulatory nucleic acids |
| 07/30/2009 | US20090191187 Antibodies against interleukin-1 receptor and uses thereof |
| 07/30/2009 | US20090191186 Antibodies to the PcrV Antigen of Pseudomonas aeruginosa |
| 07/30/2009 | US20090191185 Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling |
| 07/30/2009 | US20090191184 DcR3 polypeptide, A TNFR homolog |
| 07/30/2009 | US20090191183 Substituted indoles |
| 07/30/2009 | US20090191182 Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1 |
| 07/30/2009 | US20090191181 Methods of modulating smyd3 for treatment of cancer |
| 07/30/2009 | US20090191178 Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| 07/30/2009 | US20090191172 Method of Controlling Administration of Cancer Antigen |
| 07/30/2009 | US20090191152 Intralymphatic chemotherapy drug carriers |
| 07/30/2009 | US20090191146 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 07/30/2009 | US20090191121 Targeting and Imaging Tumor Vasculature Using Conjugates That Bind to Aminophospholipids |
| 07/30/2009 | US20090191120 Cancerous disease modifying antibodies |
| 07/30/2009 | US20090191119 Cancerous disease modifying antibodies |
| 07/30/2009 | US20090191118 Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| 07/30/2009 | US20090191117 Anti-Integrin Antibodies, Compositions, Methods and Uses |
| 07/30/2009 | CA2713189A1 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 07/30/2009 | CA2713097A1 Vaccines |
| 07/30/2009 | CA2712989A1 Optimized cd40 antibodies and methods of using the same |
| 07/30/2009 | CA2712221A1 Humanized antibodies specific for von willebrand factor |
| 07/30/2009 | CA2711826A1 Ferroportin antibodies and methods of use |
| 07/29/2009 | EP2083018A2 Compositions and methods relating to STOP-1 |
| 07/29/2009 | EP2083017A1 Antibody having enhanced adcc activity and method for production thereof |
| 07/29/2009 | EP2083016A1 Bacterial superantigen vaccines |
| 07/29/2009 | EP2082750A1 Oral recombinant helicobacter pylori vaccine and preparing method thereof |
| 07/29/2009 | EP2082749A2 Prevention and treatment of Alzheimer's disease |
| 07/29/2009 | EP2082747A2 Treatment for Alzeimer's disease |
| 07/29/2009 | EP2082042A1 Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens |
| 07/29/2009 | EP2081963A2 Methods for reducing phosphate absorption |
| 07/29/2009 | EP2081962A2 Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease |
| 07/29/2009 | EP2081960A1 Intranasal delivery of polypeptides and proteins |
| 07/29/2009 | EP2081953A2 Immunogenic pcpa polypeptides and uses thereof |
| 07/29/2009 | EP2081649A2 Modulation of cd1b or cd1d expression in autoimmune disorders |
| 07/29/2009 | EP2081596A2 Method of detecting ocular diseases and pathologic conditions and treatment of same |
| 07/29/2009 | EP2081595A2 Combination treatment of cd38-expressing tumors |
| 07/29/2009 | EP2081594A1 Novel method for treating h.pylori infections |
| 07/29/2009 | EP2081593A2 Live bacterial vaccines for viral infection prophylaxis or treatment |
| 07/29/2009 | EP2081592A1 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses |
| 07/29/2009 | EP2081591A2 Li-key enhanced vaccine potency |
| 07/29/2009 | EP2081590A2 Cancer stem cell-targeted cancer therapy |
| 07/29/2009 | EP2081588A1 Antimicrobial composition and uses thereof |
| 07/29/2009 | EP2081577A1 Prostaglandin e2 (pge2) as an adjuvant in monoclonal antibody generation |
| 07/29/2009 | EP2081553A2 Stable antibody formulations |
| 07/29/2009 | EP1689430B1 Tyrosinase mutant and methods of use thereof |
| 07/29/2009 | EP1670511B1 Cripto antagonism of activin and tgf-b signaling |
| 07/29/2009 | EP1631264B1 Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid |
| 07/29/2009 | EP1432441B1 Use of hmgb1 for the activation of dendritic cells |
| 07/29/2009 | EP1389043B1 Foot and mouth disease virus vaccine |
| 07/29/2009 | EP1307223B1 Parenteral vaccine formulations and uses thereof |
| 07/29/2009 | EP1292676B1 Mutation associated with epilepsy |
| 07/29/2009 | EP1268844B1 Modulating production of pneumococcal capsular polysaccharide |
| 07/29/2009 | EP1189641B1 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 07/29/2009 | EP1086223B1 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 07/29/2009 | EP1073463B1 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| 07/29/2009 | EP1002110B2 Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins |
| 07/29/2009 | EP0980434B1 Intracellular production of hepatitis c e2 truncated polypeptid |
| 07/29/2009 | EP0879284B1 Gene expression vectors which generate an antigen specific immune response and methods of using the same |
| 07/29/2009 | CN101495145A Methods for reducing viral load in HIV-1-infected patients |
| 07/29/2009 | CN101495144A Antitumor composition comprising a taxotere derivative and herceptin |
| 07/29/2009 | CN101495143A Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| 07/29/2009 | CN101495142A Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
| 07/29/2009 | CN101495141A Binding proteins specific for insulin-like growth factors and uses thereof |
| 07/29/2009 | CN101495140A Use of PPD for the adjuvantation of a nucleic acid vaccine |
| 07/29/2009 | CN101495139A Differentiating therapeutic composition |